Australian Firm Studies Venom’s Use to Treat Pain, Inflammation

Developer of Peptides Based on Animal Venoms Launches U.S. Presence
Managed Care Law Weekly, 12/25/05

Xenome Limited announced it has extended its business development operations to the United States and strengthened its management team with four key appointments.

David Slack has been named chief business officer, Richard Lewis was named chief scientific officer, Kathryn Radford was named vice president of strategic marketing, and Katherine Nielsen was named director, intellectual property. . .

Lewis an original co-founder of Xenome, will be the key driver in identifying, prioritizing and developing a continually evolving stream of novel drug candidates from Xenome's chemically diverse library of synthetic venom peptides. He has been considered a key opinion leader in the area of venom peptide pharmacology for over 20 years. Lewis has managed several commercial venom research programs at the Institute for Molecular Bioscience (IMB), University of Queensland where he spearheaded the development of new classes of peptide therapeutic candidates. . .

Xenome discovers peptides from Australian animal venoms. Based in Brisbane, Australia, Xenome translates the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules used by biotechnology and pharmaceutical companies. Xenome uses the peptide molecule in its drug development activities, which are focused on pain management and inflammatory disease.